辅助治疗联合非手术牙周治疗在2型糖尿病患者中的疗效:贝叶斯网络Meta分析
结果显示,龈下刮治联合全身甲硝唑或抗氧化剂α-硫辛酸分别使HbA1c额外改善1.4%和2.4%,探诊深度额外减少0.89 mm和0.92 mm,但证据确定性低,无法作出强推荐。
要点
- 甲硝唑或α-硫辛酸辅助龈下刮治可改善HbA1c和探诊深度。
- 其他辅助治疗仅改善牙周结局,对HbA1c无明显影响。
- 证据确定性低,尚无强推荐。
核心结论
- 甲硝唑或α-硫辛酸辅助龈下刮治是提供临床有意义HbA1c和探诊深度改善的最佳辅助选择。
- 由于每种辅助治疗的研究稀缺且证据确定性低,无法作出强推荐。
研究设计与样本
- 系统检索截至2023年2月,比较龈下刮治联合局部或全身辅助治疗与单纯龈下刮治。
主要发现
- 龈下刮治联合全身甲硝唑使HbA1c额外改善1.4%(95% CrI 0.48; 2.20),探诊深度额外减少0.89 mm(95% CrI 0.23; 1.50)。
- 龈下刮治联合抗氧化剂α-硫辛酸使HbA1c额外改善2.4%(95% CrI 1.50; 3.30),探诊深度额外减少0.92 mm(95% CrI 0.02; 0.92)。
- 其他辅助治疗对牙周结局有额外益处,但对HbA1c无明显影响。
关键数值与推荐
- 主要结局为治疗后3至6个月绝对HbA1c水平和全口探诊深度变化。
- 甲硝唑辅助:HbA1c改善1.4%(95% CrI 0.48; 2.20),探诊深度减少0.89 mm(95% CrI 0.23; 1.50)。
- α-硫辛酸辅助:HbA1c改善2.4%(95% CrI 1.50; 3.30),探诊深度减少0.92 mm(95% CrI 0.02; 0.92)。
临床怎么用
- 对2型糖尿病牙周炎患者,可考虑龈下刮治联合甲硝唑或α-硫辛酸以改善HbA1c和探诊深度。
- 其他辅助治疗可能改善牙周结局,但不影响血糖控制。
- 临床决策应结合患者具体情况和低确定性证据谨慎选择。
局限性
- 每种辅助治疗的研究数量稀缺。
- 结果证据确定性低,无法作出强推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: This Bayesian network meta-analysis of randomized controlled trials assessed the effect of adjuvant periodontal treatment in both periodontal and HbA1c outcomes in adult individuals with type 2 diabetes (T2DM). MATERIALS AND METHODS: A systematic search was done up to February 2023 comparing sub-gingival debridement (SD) in combination with local or systemic adjuvant treatment with SD alone for individuals with T2DM. The primary outcomes were changes in absolute HbA1c levels and full-mouth probing depth reported at 3- to 6-month post-treatment. RESULTS: Seventy-two eligible publications evaluating 27 adjuvant treatments were retrieved. The combination of SD and systemic antibiotic metronidazole or SD and antioxidant alpha lipoic acid provided, respectively, 1.4% (95% credible interval [CrI] 0.48; 2.20) and 2.4% (95% CrI 1.50; 3.30) more significant improvement on HbA1c levels, and 0.89 mm (95% CrI 0.23; 1.50) and 0.92 mm (95% CrI 0.02; 0.92) greater periodontal probing depth reductions. Other adjuvant treatments provided added benefit to the periodontal outcomes without discernible effects on HbA1c. CONCLUSIONS: Adjuvant use of metronidazole or alpha lipoic acid was the best adjunct option to provide clinically meaningful HbA1c levels and probing depth reductions. However, no strong recommendation can be drawn due to the scarcity of studies for each adjuvant treatment and the low certainty of the resultant evidence.
引用
- Zanatta FB, Antoniazzi RP, Oliveira LM, et al. The efficacy of combining adjuvants with non-surgical periodontal therapy in individuals with type 2 diabetes: A Bayesian network meta-analysis. J Clin Periodontol. 2024. PMID: 38342946. doi:10.1111/jcpe.13946
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。